NCT03921736View on ClinicalTrials.gov

Reversal of an Unfavorable Effect of Hydrochlorothiazide Compared to Angiotensin Converting Enzyme Inhibitor on Serum Uric Acid and Oxypurines Levels by Estrogen-progestin Therapy in Hypertensive Postmenopausal Women.

PHASE4CompletedINTERVENTIONAL

Enrollment

180

Participants

Timeline

Start Date

January 10, 2000

Primary Completion Date

March 6, 2001

Study Completion Date

November 17, 2005

Conditions

HypertensionHyperuricemiaMenopause

Interventions

DRUG

Perindopril

4 mg/day p.o. for 12 months

DRUG

Hydrochlorothiazide

hydrochlorothiazide 25 mg/day p.o. for 12 months

DRUG

Estracomb TTS

Transdermal patches releasing 17β-estradiol (0.05 mg/24 hours) and norethisterone (0.25 mg/24 hours) for 12 months

All Listed Sponsors

lead

Anna Posadzy-Małaczyńska

OTHER

NCT03921736 - Reversal of an Unfavorable Effect of Hydrochlorothiazide Compared to Angiotensin Converting Enzyme Inhibitor on Serum Uric Acid and Oxypurines Levels by Estrogen-progestin Therapy in Hypertensive Postmenopausal Women. | Biotech Hunter | Biotech Hunter